Mahesh B Palkar

Dr. Mahesh B Palkar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PGPankaj S. Girase
Pankaj S. Girase
SDSanjeev Dhawan
Sanjeev Dhawan
VKVishal Kumar
Vishal Kumar
SSSuraj R. Shinde
Suraj R. Shinde
MPMahesh B Palkar
Mahesh B Palkar
RKRajshekhar Karpoormath
Rajshekhar Karpoormath

1 March 2024 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DBDarshan Bhirud
Darshan Bhirud
GAGyan Agrawal
Gyan Agrawal
HSHarshil Shah
Harshil Shah
APArtiben Patel
Artiben Patel
MPMahesh B Palkar
Mahesh B Palkar
Bhupendra G PrajapatiBhupendra G Prajapati
Bhupendra G Prajapati
Since their discovery in valsartan-containing drugs, nitrosamine impurities have emerged as a significant safety problem in pharmaceutical products, prompting extensive recalls and suspensions. Valsartan, candesartan, irbesartan, olmesartan, and other sartans have been discovered to have additional nitrosamine impurities, such as N-nitroso-N-methyl-4-aminobutyric acid (NMBA), N-nitroso-Di-isopropyl amine (NDIPA), N-nitroso-Ethyl-Isopropyl amine (NEIPA), and N-nitroso-Diethyl amine (NDEA). Concerns about drug safety have grown in response to reports of nitrosamine contamination in pharmaceuticals, such as pioglitazone, rifampin, rifapentine, and varenicline. This review investigates the occurrence and impact of nitrosamine impurities in sartans and pharmaceutical goods, as well as their underlying causes. The discussion emphasizes the significance of comprehensive risk assessment and mitigation approaches at various phases of medication development and manufacturing. The link between amines and nitrosamine impurities is also investigated, with an emphasis on pH levels and the behaviour of primary, secondary, tertiary, and quaternary amines. Regulations defining standards for nitrosamine assessment and management, such as ICH Q3A-Q3E and ICH M7, are critical in resolving impurity issues. Furthermore, the Global Substance Registration System (GSRS) is underlined as being critical for information sharing and product safety in the pharmaceutical industry. The review specifically focuses on the relationship between ranitidine and N-nitroso dimethyl amine (NDMA) in the context of the implications of nitrosamine contamination on patient safety and medicine supply. The importance of regulatory authorities in discovering and correcting nitrosamine impurities is highlighted in order to improve patient safety, product quality, and life expectancy. Furthermore, the significance of ongoing study and attention to nitrosamine-related repercussions for increasing pharmaceutical safety and overall public health is emphasized.

7 June 2023 in Journal of Molecular Structure
Verified
Journal Article
Closed access
AGAb Majeed Ganai
Ab Majeed Ganai
TPTabasum Khan Pathan
Tabasum Khan Pathan
SMSachin Balaso Mohite
Sachin Balaso Mohite
VVVeronika Vojáčková
Veronika Vojáčková
EŘEva Řezníčková
Eva Řezníčková
RKRajshekhar Karpoormath
Rajshekhar Karpoormath

29 December 2023 in Journal of Molecular Structure
Verified
Journal Article
Closed access
SMSrinivas Reddy Merugu
Srinivas Reddy Merugu
SMSithabile Mokoena
Sithabile Mokoena
VOVincent A. Obakachi
Vincent A. Obakachi
BSBaji Baba Shaik
Baji Baba Shaik
BKBabita Kushawaha
Babita Kushawaha
RKRajshekhar Karpoormath
Rajshekhar Karpoormath

22 April 2025 in Chemnanomat
Verified
Journal Article
Closed access
UBUtkarsh U. Bhamare
Utkarsh U. Bhamare
TPTejas S. Patil
Tejas S. Patil
DCDeepvardhan P. Chaudhari
Deepvardhan P. Chaudhari
MPMahesh B Palkar
Mahesh B Palkar

2 April 2025 in Receptors
Verified
Journal Article
Open access
PDF file
CMCHITARANJAN MAHAPATRA
CHITARANJAN MAHAPATRA
JGJineetkumar Gawad
Jineetkumar Gawad
CBChandrakant Bonde
Chandrakant Bonde
MPMahesh B Palkar
Mahesh B Palkar
Bioelectric membrane potentials regulate cellular growth, differentiation, and movement. Disruptions in bioelectric signaling are strongly linked to cancer development, as abnormal membrane potentials and ion channel activity can drive tumor progression. In breast cancer, ion channel dysfunction and neuroreceptor-related pathways play significant roles in the cell cycle, epithelial–mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment, and tumor progression. Neuroreceptors are critical not only in initiating and advancing cancer but also in conferring resistance to treatments. Neuroreceptors also play a key role, with dopamine receptor D2 activation reducing breast tumor growth by 40% in preclinical models, while serotonin signaling has been shown to promote epithelial–mesenchymal transition (EMT), increasing invasiveness. Advances in understanding these biological mechanisms could lead to more cost-effective and less invasive therapeutic strategies to treat tumors. This review explores the expanding evidence connecting bioelectric activity to breast cancer, focusing on neuroreceptor pharmacology as a transformative therapeutic approach. Examining the modulation of bioelectricity through neuroreceptor pharmacology to influence breast cancer progression and integrating these insights into therapeutic development offers a promising path for addressing treatment challenges and improving precision in managing aggressive cancer subtypes.